| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1041 | |
| Phytochemical name or plant extracts | Ziyuglycoside I | |
| PMID | 27879682 | |
| Literature evidence | This suggests that ziyuglycoside I might be a potential drug candidate for treating TNBC. | |
| IUPAC name | [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-1-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-10-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid saponin | |
| Source of phytochemicals or plant Extracts | Sanguisorba officinalis | |
| Geographical availability | Alaska, Albania, Altay, Amur, Austria, Baltic States, Belarus, Belgium, British Columbia, Bulgaria, Buryatiya, California, Central European Rus, China North-Central, China South-Central, China Southeast, Chita, Czechoslovakia, East European Russia, France, Germany, Great Britain, Greece, Hungary, Iceland, Inner Mongolia, Iran, Ireland, Irkutsk, Italy, Japan, Kamchatka, Kazakhstan, Khabarovsk, Kirgizstan, Korea, Krasnoyarsk, Krym, Magadan, Maine, Manchuria, Michigan, Mongolia, Netherlands, North Caucasus, North European Russi, Northwest European R, Northwest Territorie, Norway, Nova Scotia, Oregon, Pennsylvania, Poland, Primorye, Qinghai, Romania, Sakhalin, South European Russi, Spain, Sweden, Switzerland, Taiwan, Tibet, Transcaucasus, Turkey, Tuva, Ukraine, Washington, West Siberia, Xinjiang, Yakutskiya, Yugoslavia, Yukon | |
| Plant parts | Root | |
| Other cancers | Breast cancer | |
| Target gene or protein | p53, p21WAF1, Bax, Bcl-2 | |
| Gene or Protein evidence | These effects were found to be partially mediated through the up-regulation of p53 and p21WAF1, elevated Bax/Bcl-2 ratio, and the activation of both intrinsic (mitochondrial-initiated) and extrinsic (Fas/FasL-initiated) apoptotic pathways. | |
| Target pathways | Intrinsic (mitochondrial-initiated) and extrinsic (Fas/FasL-initiated) apoptotic pathways. | |
| IC50 | 13.96 µM against MDA-MB-231 | |
| Potency | Our study suggested that ziyuglycoside I-triggered MDA-MB-231 cell cycle arrest and apoptosis were probably mediated by p53. This suggests that ziyuglycoside I might be a potential drug candidate for treating TNBC. | |
| Cell line/ mice model | MDA-MB-231 | |
| Additional information | All of these results suggest that ziyuglycoside I isolated from the S. officinalis root extract could be used as an active ingredient in new anti-wrinkle cosmetic products. | |
| PubChem ID | 71609288 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:741402-1 | |
| Safety | NA |